Aptevo Therapeutics Inc.
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -738.89% | 10.20% | |||
| Gross Profit | 738.89% | -10.20% | |||
| SG&A Expenses | 18.58% | -11.38% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 22.42% | -13.46% | |||
| Operating Income | -22.42% | 13.46% | |||
| Income Before Tax | -23.74% | 13.29% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -23.74% | 13.29% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -23.74% | 13.29% | |||
| EBIT | -22.42% | 13.46% | |||
| EBITDA | -23.05% | 13.55% | |||
| EPS Basic | 56.79% | 71.07% | |||
| Normalized Basic EPS | 56.79% | 71.07% | |||
| EPS Diluted | 56.73% | 71.07% | |||
| Normalized Diluted EPS | 56.79% | 71.07% | |||
| Average Basic Shares Outstanding | 186.32% | 199.79% | |||
| Average Diluted Shares Outstanding | 186.32% | 199.79% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||